{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T03:16:19Z","timestamp":1648610179521},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00393-014-1437-5","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T16:58:04Z","timestamp":1423760284000},"page":"8-13","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pathogene Zellen der rheumatischen Entz\u00fcndung als Ziele moderner Therapien"],"prefix":"10.1007","volume":"74","author":[{"given":"J.R.","family":"Kalden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,14]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/art.1780340202","volume":"34","author":"Horneff","year":"1991","unstructured":"Horneff G, Burmester G, Emmrich F et al (1991) Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34:129\u2013140","journal-title":"Arthritis Rheum"},{"key":"1437_CR2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","volume":"30","author":"Gregersen","year":"1987","unstructured":"Gregersen PK, Silver J, Winchester R (1987) The shared epitope hypothesis. Arthritis Rheum 30:1205","journal-title":"Arthritis Rheum"},{"key":"1437_CR3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3899\/jrheum.130896","volume":"41","author":"Tarr","year":"2014","unstructured":"Tarr G, Makada M, Musenge E et al (2014) Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: a retrospective study in South Africans. J Rheumatol 41:1645\u20131649","journal-title":"J Rheumatol"},{"key":"1437_CR4","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(87)91158-5","volume":"II","author":"Herzog","year":"1987","unstructured":"Herzog CH, Walker CH, Pichler W et al (1987) Monoclonal anti-CD4 in arthritis. Lancet II:1461\u20131462","journal-title":"Lancet"},{"key":"1437_CR5","first-page":"1845","volume":"19","author":"Horneff","year":"1992","unstructured":"Horneff G, Emmrich F, Reiter C et al (1992) Persistent depletion of CD4+T cells and inversion of the CD4\/CD8 T cell ratio induced by anti-CD4 therapy. J Rheumatol 19:1845\u20131850","journal-title":"J Rheumatol"},{"key":"1437_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/32.suppl_4.39","volume":"32","author":"Horneff","year":"1993","unstructured":"Horneff G, Emmrich F, Burmester GR (1993) Advances in immunotherapy of rheumatoid arthritis: clincial and immunological findings following treatment with anti-CD4 antibodies. Br J Rheum 32(Suppl 4):39\u201347","journal-title":"Br J Rheum"},{"key":"1437_CR7","first-page":"567","volume":"24","author":"Breedveld","year":"1998","unstructured":"Breedveld FC (1998) Monoclonal antibodies to CD4. Emerg Ther Rheum Arthritis 24:567\u2013578","journal-title":"Emerg Ther Rheum Arthritis"},{"key":"1437_CR8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/art.1780361008","volume":"36","author":"Lubbe","year":"1993","unstructured":"Lubbe PA van der, Reiter C, Breedveld FC et al (1993) Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 36:1375","journal-title":"Arthritis Rheum"},{"key":"1437_CR9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/art.1780360304","volume":"36","author":"Moreland","year":"1993","unstructured":"Moreland LW, Bucy RP, Tilden A et al (1993) Use of a chimeric monoclonal anti-CD4 antiboidy in patients with refractory rheumatoid arthritis. Arthritis Rheum 36:307","journal-title":"Arthritis Rheum"},{"key":"1437_CR10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.1780380812","volume":"38","author":"Lubbe","year":"1995","unstructured":"Lubbe PA van der, Dijkmans BAC, Markusse HM et al (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38:1097","journal-title":"Arthritis Rheum"},{"key":"1437_CR11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/art.1780390107","volume":"39","author":"Choy","year":"1996","unstructured":"Choy EHS, Pitzalis C, Cauli A (1996) Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Arthritis Rheum 39:52\u201356","journal-title":"Arthritis Rheum"},{"key":"1437_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/eji.1830220110","volume":"22","author":"Broek","year":"1992","unstructured":"Broek MF van den, Langerijt LG van de, Bruggen MC van et al (1992) Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 22:57\u201361","journal-title":"Eur J Immunol"},{"key":"1437_CR13","doi-asserted-by":"crossref","unstructured":"Choy EHS (1998) New prospects for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 1087","DOI":"10.1517\/13543784.7.7.1087"},{"key":"1437_CR14","first-page":"220","volume":"29","author":"Masen","year":"2002","unstructured":"Masen U, Aldrich J, Breedveld FC et al (2002) CD4 coating, but not CD4 depletion, is a predictor of efficycy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 29:220\u2013229","journal-title":"J Rheumatol"},{"key":"1437_CR15","doi-asserted-by":"crossref","first-page":"R177","DOI":"10.1186\/ar3502","volume":"13","author":"Scheerens","year":"2011","unstructured":"Scheerens H, Su Z, Irving B et al (2011) MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthrtis Res Ther 13:R177","journal-title":"Arthrtis Res Ther"},{"key":"1437_CR16","first-page":"S244","volume":"39","author":"Panayi","year":"1996","unstructured":"Panayi GS, Choy EHS, Connolly DJA (1996) T Cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 mAB treatment. I: suppression of disease activity and acute phase response. Arthritis Rheum 39:S244","journal-title":"Arthritis Rheum"},{"key":"1437_CR17","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1002\/art.1780390107","volume":"39","author":"Choy","year":"1996","unstructured":"Choy EHS, Connolly DJA, Regan T et al (1996) T cell hypothsis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 mAB treatment. II: clinical activity is related to pharmacodynamic effects. Arthritis Rheum 39:S244","journal-title":"Arthritis Rheum"},{"key":"1437_CR18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105\u20131110","journal-title":"Lancet"},{"key":"1437_CR19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","volume":"Res","author":"Nash","year":"2013","unstructured":"Nash P, Nayiager S, Genovese MC et al (2013) Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken) 5:718\u2013728","journal-title":"Arthritis Care"},{"key":"1437_CR20","first-page":"553","volume":"32","author":"Westhovens","year":"2014","unstructured":"Westhovens R, Kremer JM, Emery P et al (2014) Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 32:553\u2013562","journal-title":"Clin Exp Rheumatol"},{"key":"1437_CR21","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","volume":"66","author":"Alten","year":"2014","unstructured":"Alten R, Kaine J, Keystone E et al (2014) Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol 66:1987\u20131997","journal-title":"Arthritis Rheumatol"},{"key":"1437_CR22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/ard.2010.139345","volume":"10","author":"Kremer","year":"2011","unstructured":"Kremer JM, Russell AS, Abud-Mendoza C et al (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AM trial. Ann Rheum Dis 10:1826\u20131830","journal-title":"Ann Rheum Dis"},{"key":"1437_CR23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G et al (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63:939\u2013948","journal-title":"Arthritis Rheum"},{"key":"1437_CR24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"11","author":"Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 11:1114\u20131123","journal-title":"N Engl J Med"},{"key":"1437_CR25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2008.09.050","volume":"60","author":"Mease","year":"2009","unstructured":"Mease PJ, Reich K (2009) Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 60:402\u2013411","journal-title":"J Am Acad Dermatol"},{"key":"1437_CR26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s003930170032","volume":"60","author":"Lorenz","year":"2001","unstructured":"Lorenz HM, Kalden JR (2001) Neue Therapieentwicklungen in der Rheumatoiden Arthritis. Z Rheumatol 60:326\u2013332","journal-title":"Z Rheumatol"},{"key":"1437_CR27","first-page":"S290","volume":"43","author":"Sigidin","year":"2000","unstructured":"Sigidin YA, Loukina GV, Skurkovich SV et al (2000) Double-blind, placebo-controlled study of antibodies to interferon-gamma vs. antibodies to TNFalpha in rheumatoid arthritis. Arthritis Rheum 43:S290","journal-title":"Arthritis Rheum"},{"key":"1437_CR28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/art.1780370703","volume":"37","author":"Kavanaugh","year":"1994","unstructured":"Kavanaugh AF, Davis LS, Nichols et al (1994) Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule I. Arthritis Rheum 37:992\u2013999","journal-title":"Arthritis Rheum"},{"key":"1437_CR29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/rheumatology\/30.6.459","volume":"30","author":"Kirkham","year":"1991","unstructured":"Kirkham BW, Pitzalis C, Kingsley GH et al (1991) Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 30:459\u2013463","journal-title":"Br J Rheumatol"},{"key":"1437_CR30","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.1780390705","volume":"39","author":"Olsen","year":"1996","unstructured":"Olsen NJ, Brooks RH, Cush JJ et al (1996) A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 39:1102\u20131108","journal-title":"Arthritis Rheum"},{"key":"1437_CR31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/art.1780360907","volume":"36","author":"Sewell","year":"1993","unstructured":"Sewell KL, Parker KC, Woodworth TG et al (1993) DAB486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum 36:1223\u20131233","journal-title":"Arthritis Rheum"},{"key":"1437_CR32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/art.1780380902","volume":"38","author":"Moreland","year":"1995","unstructured":"Moreland LW, Sewell KL, Trentham DE et al (1995) Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. Arthritis Rheum 38:1177\u20131186","journal-title":"Arthritis Rheum"},{"key":"1437_CR33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.1780381110","volume":"38","author":"Weinblatt","year":"1995","unstructured":"Weinblatt ME, Maddison PJ, Bulpitt KJ et al (1995) CAMPATH-1, a Humanized monoclonal antibody, in refractory rheumatoid arthritis. Arthritis Rheum 38:1589\u20131594","journal-title":"Arthritis Rheum"},{"key":"1437_CR34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.1780380903","volume":"38","author":"Matteson","year":"1995","unstructured":"Matteson EL, Yocum DE, St Clair W et al (1995) Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 38:1187\u20131193","journal-title":"Arthritis Rheum"},{"key":"1437_CR35","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK et al (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457\u20132466","journal-title":"Blood"},{"key":"1437_CR36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/37.2.126","volume":"37","author":"Edwards","year":"1998","unstructured":"Edwards JCW, Cambridge G (1998) Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 37:126\u2013130","journal-title":"Br J Rheumatol"},{"key":"1437_CR37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000082103","volume":"8","author":"Edwards","year":"2005","unstructured":"Edwards JCW, Leandro MJ, Cambrige G (2005) B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 8:175\u2013192","journal-title":"Curr Dir Autoimmun"},{"key":"1437_CR38","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","volume":"46","author":"De","year":"2002","unstructured":"De Vita S, Zaja F, Sacco S et al (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 46:2029\u20132033","journal-title":"Arthritis Rheum"},{"key":"1437_CR39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protexts mice with lupus-like disease from nephritis. Nat Med 14:748\u2013755","journal-title":"Nat Med"},{"key":"1437_CR40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF01972398","volume":"8","author":"Allison","year":"1978","unstructured":"Allison AC, Ferluga J, Prydz H et al (1978) The role of macrophage activation in chronic inflammation. Agents Actions 8:27\u201335","journal-title":"Agents Actions"},{"key":"1437_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.1780400104","volume":"40","author":"Burmester","year":"1997","unstructured":"Burmester GR, Stuhlmueller B, Keyszer G et al (1997) Mononuclear phagocytes and rheumatoid synovitis. Arthritis Rheum 40:5\u201318","journal-title":"Arthritis Rheum"},{"key":"1437_CR42","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.1780250502","volume":"25","author":"Klareskog","year":"1982","unstructured":"Klareskog L, Forsum U, Kabelitz D et al (1982) Immune functions of human synovial cells: phenotyic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum 25:488\u2013501","journal-title":"Arthritis Rheum"},{"key":"1437_CR43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2249.1993.tb05884.x","volume":"91","author":"Horneff","year":"1993","unstructured":"Horneff G, Sach U, Kalden JR et al (1993) Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment: decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 91:207\u2013213","journal-title":"Clin Exp Immunol"},{"key":"1437_CR44","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1172\/JCI116307","volume":"91","author":"Hahn","year":"1993","unstructured":"Hahn G, Stuhlmueller B, Hain N et al (1993) Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest 91:862\u2013870","journal-title":"J Clin Invest"},{"key":"1437_CR45","first-page":"16","volume":"29","author":"Arend","year":"2002","unstructured":"Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol 29(Suppl 65):16\u201321","journal-title":"J Rheumatol"},{"key":"1437_CR46","first-page":"2068","volume":"38","author":"Haringman","year":"2005","unstructured":"Haringman JJ, Gerlag DM, Zwinderman AH et al (2005) Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 38:2068\u20132072","journal-title":"Ann Rheum Dis"},{"key":"1437_CR47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00262295","volume":"14","author":"Bell","year":"1995","unstructured":"Bell AL, Magill MK, McKane WR et al (1995) Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 14:177\u2013182","journal-title":"Rheumatol Int"},{"key":"1437_CR48","first-page":"121","volume":"51","author":"Fiehn","year":"1992","unstructured":"Fiehn C, Wermann M, Pezzutto A et al (1992) Plasma GM-CSF concentrations in rheuamatoid arthritis, systemic lupus erythematosus and spondyarthropathy. Z Rheumatol 51:121\u2013126","journal-title":"Z Rheumatol"},{"key":"1437_CR49","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","volume":"72","author":"Burmester","year":"2013","unstructured":"Burmester GR, Weinblatt ME, McInnes IB et al (2013) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72:1445\u20131452","journal-title":"Ann Rheum Dis"},{"key":"1437_CR50","first-page":"41","volume":"9","author":"Di","year":"2014","unstructured":"Di Franco M, Gerardi MC, Lucchino B et al (2014) Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis. Core Evid 9:41\u201348","journal-title":"Core Evid"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-014-1437-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-014-1437-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:34:37Z","timestamp":1598744077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-014-1437-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s00393-014-1437-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}